Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression

NCT04029428 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: 90Y-DOTATATE
DRUG: (177Lu-DOTAOTyr3)Octreotate
DRUG: 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)

Sponsor

University of Warmia and Mazury

Collaborators

[object Object]